Craft

Bioventix

Stock Price

£32.3

2024-10-29

Market Capitalization

£193.1 M

2024-10-16

Revenue

£13.1 M

FY, 2025

Bioventix Summary

Company Summary

Overview
Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drug of abuse testing. It uses its technology in the fields of clinical diagnostics. The company develops products for Thyroid, Fertility, Oncology, Vitamin D, Drugs of Abuse, and other diseases. Its product, Vitamin D SMA is a steroid hormone involved in the intestinal absorption of calcium and the regulation of calcium homeostasis but it has also evolved into a hormone that has a diversity of biological effects.
Type
Public
Status
Active
Founded
2003
HQ
Farnham, GB | view all locations
Website
https://www.bioventix.com/
Cybersecurity rating
Sectors

Key People

  • Peter Harrison

    Peter Harrison, Chief Executive Officer and Director

  • Ian Nicholson

    Ian Nicholson, Chairman and Independent Non-Executive Director

  • Nicholas McCooke

    Nicholas McCooke, Non-Executive Director

  • Bruce Hiscock

    Bruce Hiscock, Chief Finance Officer and Director

LocationsView all

1 location detected

  • Farnham, England HQ

    United Kingdom

    7 Romans Business Park, East St

Bioventix Financials

Summary Financials

Revenue (H1, 2026)
£6.2M
Gross profit (H1, 2026)
£5.7M
Net income (H1, 2026)
£3.6M
Cash (H1, 2026)
£5.3M
EBIT (H1, 2026)
£4.7M

Footer menu